# US 2008/0306035 A1 · Methods and Compositions for Treating Female Infertility Using Clomiphene

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306035 A1
- Document ID: US20080306035A1
- Status: Published application
- Kind: A1
- Application number: 11/997,858
- Filed: 2006-08-02
- Published: 2008-12-11
- Earliest claimed: 2005-08-05
- Assignees: Repros Therapeutics Inc.
- Inventors: Joseph S. Podolski
- Web page: https://patentgrep.com/patent/US20080306035A1

## CPC

- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61P 5/02: of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P 5/06: of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P 5/30: Oestrogens
- A61P 5/32: Antioestrogens
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 17/08: Antiseborrheics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the use of compositions comprising clomiphene for treating female infertility. The invention is also directed to a regimen of treatment for female infertility using trans-clomiphene, a mixture of cis- and trans-clomiphene, and cis-clomiphene.

## Claims

### Claim 1

A method of treating female infertility comprising:
(a) administering to a patient in need thereof prior to ovulation a first composition comprising clomiphene, wherein the clomiphene is comprised of at least about 70% trans-clomiphene;
(b) administering to the patient between ovulation and fertilization a second composition comprising clomiphene, wherein the clomiphene is comprised of trans-clomiphene and cis-clomiphene; and optionally
(c) administering to the patient after fertilization a third composition comprising clomiphene, wherein the clomiphene is comprised of at least about 50% cis-clomiphene.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compositions are administered in a single or multiple daily doses.

### Claim 3 (depends on 2)

The method of claim 2, wherein the number of daily doses is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10.

### Claim 4 (depends on 1)

The method of claim 1, wherein the first composition is administered starting at about day 2 to about day 5 of the patient's menstrual cycle.

### Claim 5 (depends on 1)

The method of claim 1, wherein the clomiphene of the first composition consists essentially of trans-clomiphene.

### Claim 6 (depends on 1)

The method of claim 1, wherein the clomiphene of the first composition is trans-clomiphene.

### Claim 7 (depends on 2)

The method of claim 2, wherein the first composition is administered in multiple doses.

### Claim 8 (depends on 2)

The method of claim 2, wherein the first composition is administered in a single dose.

### Claim 9 (depends on 1)

The method of claim 1, wherein the clomiphene of the second composition is comprised of about 50-80% of cis-clomiphene and about 20-50% of trans-clomiphene.

### Claim 10 (depends on 2)

The method of claim 2, wherein the second composition is administered in multiple doses.

### Claim 11 (depends on 10)

The method of claim 10, wherein at least one successive dose comprises an increased percentage of cis-clomiphene compared to the previous dose.

### Claim 12 (depends on 2)

The method of claim 2, wherein the second composition is administered in a single dose.

### Claim 13 (depends on 1)

The method of claim 1, wherein the clomiphene of the third composition consists essentially of cis-clomiphene.

### Claim 14 (depends on 1)

The method of claim 1, wherein the clomiphene of the third composition is cis-clomiphene.

### Claim 15 (depends on 1)

The method of claim 1, wherein the clomiphene of the third composition is comprised of trans-clomiphene.

### Claim 16 (depends on 1)

The method of claim 1, wherein the third composition further comprises progesterone.

### Claim 17 (depends on 2)

The method of claim 2, wherein the third composition is administered in a single dose.

### Claim 18 (depends on 2)

The method of claim 2, wherein the third composition is administered in multiple doses.

### Claim 19 (depends on 1)

The method of claim 1, wherein the third composition is administered throughout the first trimester of the patient's pregnancy.
